TeriFort 1+ Study: Efficacy and Safety of an Extensively Hydrolyzed Formula in the Management of Cow's Milk Protein Allergy in Young Children: A Prospective, Single-Arm Interventional Study (TeriFort 1+)

Efficacy and Safety of an Extensively Hydrolyzed Formula in the Management of Cow's Milk Protein Allergy in Young Children: A Prospective, Single-Arm Interventional Study

This study aims to evaluate the clinical effect, as reported by physicians, of an extensively hydrolyzed formula in young children aged 1~3 years with diagnosed with or highly suspected CMPA in a real-world clinical practice setting. The study will also evaluate the growth parameters, stool frequency and consistency, formula intake volume, gastrointestinal tolerance (including fussiness, flatulence, colic) and sleep disturbances, and any adverse events that may arise during the intervention period. This is a prospective, single-arm study including 50 young children at 1 hospital in China. Each participant will be followed for 90 days.

Study Overview

Detailed Description

Cow's milk protein allergy (CMPA) is one of the most common food allergy in infancy and early childhood. The global overall prevalence ranges from 0.5% to 3% , and in some regions it can be as high as 4.9%. Currently, there are no nationwide epidemiological survey data on CMPA in China. However, local studies conducted in Chongqing, Hangzhou, and Zhuhai have reported a prevalence of 0.83% ~ 3.5% in infants aged 0 ~ 2 years. The pathogenesis of CMPA mainly includes IgE-mediated immediate-type hypersensitivity, non-IgE-mediated delayed-type hypersensitivity, and mixed-type reactions mediated by both mechanisms. Clinical manifestations may involve multiple organs and systems, including the skin, gastrointestinal tract, and respiratory tract. Dietary avoidance of cow's milk protein continues to be the main therapeutic approach, utilizing extensively hydrolyzed or amino acid-based formulas as determined by the degree of allergy.

Ages 1 ~ 3 years represent a critical window for the persistence of allergic symptoms and disease resolution in toddlers; approximately 85% ~ 90% of children with CMPA achieve clinical tolerance by around 3 years of age. Meanwhile, the age group of 1 ~ 3 years is also a critical period for dietary transition and the establishment of immune tolerance, during which children are particularly vulnerable to nutritional deficiencies. Therefore, special attention should be given to this age group, so that early diagnosis and appropriate interventions can be implemented to mitigate the impact of the disease on growth and development.

This is a prospective, longitudinal, single-arm study conducted at 1 hospital in China. The study will enroll young children aged 1~ 3 years with diagnosed with or highly suspected CMPA. Each participant will be followed for 90 days after the initiation of the investigational product. Parents or legal guardians will complete questionnaires regarding symptoms, gastrointestinal function, and product acceptability, while investigators will record clinical symptoms and anthropometric data using an electronic case report form (eCRF).

Collected data will include:

  • Sociodemographic and baseline characteristics: sex, birth weight and length, gestational age, and family history of allergy.
  • Anthropometric parameters: weight, length, and head circumference.
  • Clinical assessments: Modified CoMiSS, SCORAD, and BSFS scores.
  • Parent-reported outcomes: IGSQ-13, FAQL-PB, BISQ scores,and acceptability/satisfaction surveys.
  • Safety outcomes: adverse events and concomitant medications.

A healthy reference group will include, which underwent only the modified CoMiSS assessment without exposure to the investigational product or involvement in efficacy/safety analyses, yielding normative reference benchmarks for the healthy population.

Study Type

Interventional

Enrollment (Estimated)

50

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, China, 200000
        • Shanghai Children's Medical Center Affiliated to Shanghai Jiao Tong University School of Medicine
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

1 year to 3 years (Child)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • 12 months≤ Age <36 months at enrollment.

  • Born at term at 37 ~ 42 weeks of gestation, with birth weight 2,500~4,000g.

  • Diagnosed with or highly suspected mild-to-moderate CMPA by a physician, meeting any of the following prior to enrollment:

    1. Positive serum cow's-milk-specific IgE (sIgE) >0.35 kUA/L (>0.7 kIU/L), combined with a detailed medical history; or a positive skin prick test (SPT);
    2. Positive result from a cow's milk protein elimination-challenge test;
    3. A documented medical history confirming CMPA within the 2 weeks prior to enrollment.
  • Hospitalization is not required and home intervention is considered appropriate by the investigator.

  • Written informed consent signed by a parent or legal guardian.

Exclusion Criteria:

  • History of severe cows-milk-induced allergic reaction, such as anaphylactic shock.
  • Underlying disease or history that may increase risk or affect gastrointestinal tolerance, growth, or development, including chronic systemic disease, congenital heart disease, chronic inflammatory bowel disease, malignant tumor, gastrointestinal malformation, or major congenital malformation.
  • Laboratory abnormalities judged by the investigator to make participation inappropriate.
  • Use of an extensively hydrolyzed formula or amino-acid formula within the preceding month.
  • Participation in another interventional clinical trial within the preceding 90 days or currently.
  • Inability to complete scheduled study visits
  • Known intolerance to another ingredient in the study formula
  • Any other condition judged inappropriate by the investigator.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Diagnosed with or highly suspected CMPA: Extensively Hydrolyzed Formula intervention
  • Avoidance of all foods and products containing cow's milk protein will be required;
  • An individualized diet will be selected and arranged according to the young children's usual eating habits, with dietary guidance provided by the investigator based on the young children's allergic status;
  • The intake of the investigational product will be recommended to be maintained at approximately 500 mL/day.
  • Avoidance of all foods and products containing cow's milk protein will be required;
  • An individualized diet will be selected and arranged according to the young children's usual eating habits, with dietary guidance provided by the investigator based on the young children's allergic status;
  • The intake of the investigational product will be recommended to be maintained at approximately 500 mL/day.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in investigator-reported allergy symptom scores
Time Frame: Baseline, Day 30 ± 5, Day 90 ± 7

Change from baseline to D30 and D90 in investigator-assessed allergy symptoms in toddlers with diagnosed with or highly suspected cow's milk protein allergy, measured using four instruments.

Baseline, Day 30 ± 5, Day 90 ± 7

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in investigators measured or parent/caregiver-reported allergy symptom scores
Time Frame: Baseline, Day 30 ± 5, Day 60 ± 7, Day 90 ± 7

Change from baseline to D30, D60 and D90 in investigators measured or parent/caregiver-reported symptoms, which will be analyzed according to improvement (reduction in score) or no improvement.

Baseline, Day 30 ± 5, Day 60 ± 7, Day 90 ± 7
Change in z-scores for weight, length/height, and head circumference
Time Frame: Baseline, Day 30 ± 5, Day 90 ± 7

Change in z-scores for weight, length/height, and head circumference calculated according to World Health Organization (WHO) growth standards. Differences between baseline, D30 and D90 will be summarized using descriptive statistics.

Baseline, Day 30 ± 5, Day 90 ± 7
Change in stool characteristics
Time Frame: Baseline, Day 30 ± 5, Day 60 ± 7, Day 90 ± 7

Parent-reported stool characteristics (consistency and color), stool frequencies and stool types will be summarized for each visit.

Baseline, Day 30 ± 5, Day 60 ± 7, Day 90 ± 7
Stool Samples Test Results
Time Frame: Baseline, Day 30 ± 5, Day 90 ± 7

Abnormalities in routine stool examination and fecal occult blood test.

Baseline, Day 30 ± 5, Day 90 ± 7
Change in parental quality of life related to children allergy
Time Frame: Baseline, Day 30 ± 5, Day 60 ± 7, Day 90 ± 7

Change in the Food Allergy Quality of Life-Parental Burden Questionnaire (FAQL-PB) score from baseline to Day 30, Day 60 and day 90. Improvement will be defined as a reduction in the total score. Descriptive statistics and frequencies of improvement will be presented.

Baseline, Day 30 ± 5, Day 60 ± 7, Day 90 ± 7
Parental satisfaction with the investigational product
Time Frame: Day 90 ± 7

Parent- or caregiver-reported satisfaction with the investigational product.

Day 90 ± 7
Dietary intake
Time Frame: Baseline, Day 30 ± 5, Day 90 ± 7

Assessment of dietary intake, including food categories and quantities (by weight), at baseline, on Day 30, and on Day 90 of the intervention.

Baseline, Day 30 ± 5, Day 90 ± 7
Adverse Events and Concomitant Medications
Time Frame: From first intervention to Day 90 ± 7

Incidence, severity, and causal attribution to the study product of AEs and SAEs, together with concomitant medication use, throughout the study period.

From first intervention to Day 90 ± 7

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

November 1, 2026

Primary Completion (Estimated)

December 1, 2027

Study Completion (Estimated)

December 1, 2027

Study Registration Dates

First Submitted

September 28, 2026

First Submitted That Met QC Criteria

September 28, 2026

First Posted (Actual)

October 2, 2026

Study Record Updates

Last Update Posted (Actual)

October 2, 2026

Last Update Submitted That Met QC Criteria

September 28, 2026

Last Verified

September 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • ESEHF2-CMPA-202601

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe